| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine.
|
Med Oncol
|
2010
|
1.38
|
|
2
|
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
|
Clin Cancer Res
|
2008
|
1.32
|
|
3
|
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
|
J Clin Oncol
|
2013
|
1.17
|
|
4
|
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
|
BMC Cancer
|
2010
|
1.14
|
|
5
|
Prognostic impact of microRNA-related gene polymorphisms on survival of patients with colorectal cancer.
|
J Cancer Res Clin Oncol
|
2010
|
1.09
|
|
6
|
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
|
Ann Hematol
|
2009
|
1.06
|
|
7
|
18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
|
J Nucl Med
|
2012
|
1.02
|
|
8
|
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
|
Ann Hematol
|
2012
|
0.95
|
|
9
|
Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
|
Biol Blood Marrow Transplant
|
2009
|
0.92
|
|
10
|
No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer.
|
Cancer Res Treat
|
2009
|
0.91
|
|
11
|
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
|
Cancer Chemother Pharmacol
|
2005
|
0.90
|
|
12
|
AQP5 expression predicts survival in patients with early breast cancer.
|
Ann Surg Oncol
|
2013
|
0.89
|
|
13
|
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
|
Cancer Chemother Pharmacol
|
2009
|
0.88
|
|
14
|
Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review.
|
Int J Hematol
|
2009
|
0.88
|
|
15
|
Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS/MS.
|
Arch Pharm Res
|
2012
|
0.88
|
|
16
|
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
|
Cancer Chemother Pharmacol
|
2007
|
0.88
|
|
17
|
Expression of aquaporin-1, aquaporin-3, and aquaporin-5 correlates with nodal metastasis in colon cancer.
|
Oncology
|
2015
|
0.87
|
|
18
|
Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
|
Oncology
|
2011
|
0.85
|
|
19
|
TNF superfamily gene polymorphism as prognostic factor in early breast cancer.
|
J Cancer Res Clin Oncol
|
2009
|
0.84
|
|
20
|
Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer.
|
Oncology
|
2013
|
0.83
|
|
21
|
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
|
Cancer Chemother Pharmacol
|
2012
|
0.83
|
|
22
|
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
|
Cancer Chemother Pharmacol
|
2008
|
0.82
|
|
23
|
Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
|
Invest New Drugs
|
2011
|
0.82
|
|
24
|
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
|
J Korean Med Sci
|
2009
|
0.81
|
|
25
|
Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse.
|
Acta Haematol
|
2010
|
0.81
|
|
26
|
Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
|
Cancer Sci
|
2010
|
0.81
|
|
27
|
Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
|
Clin Transplant
|
2008
|
0.81
|
|
28
|
Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer.
|
Ann Surg Oncol
|
2014
|
0.79
|
|
29
|
Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
|
Cancer Chemother Pharmacol
|
2013
|
0.79
|
|
30
|
Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.
|
Int J Hematol
|
2010
|
0.78
|
|
31
|
No association of the NFKB1 insertion/deletion promoter polymorphism with survival in patients with gastric cancer.
|
Jpn J Clin Oncol
|
2009
|
0.78
|
|
32
|
Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
|
Ann Hematol
|
2010
|
0.78
|
|
33
|
Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation.
|
J Clin Apher
|
2009
|
0.78
|
|
34
|
Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement.
|
Cancer Res Treat
|
2013
|
0.78
|
|
35
|
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
|
J Cancer Res Clin Oncol
|
2010
|
0.78
|
|
36
|
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
|
J Korean Med Sci
|
2009
|
0.78
|
|
37
|
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
|
Ann Hematol
|
2011
|
0.78
|
|
38
|
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
|
Korean J Intern Med
|
2012
|
0.77
|
|
39
|
Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
|
Leuk Lymphoma
|
2007
|
0.77
|
|
40
|
Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
|
Biomacromolecules
|
2015
|
0.77
|
|
41
|
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2010
|
0.77
|
|
42
|
No Association of Insulin-like Growth Factor Gene Polymorphisms with Survival in Patients with Colorectal Cancer.
|
Cancer Res Treat
|
2011
|
0.77
|
|
43
|
Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.
|
Asia Pac J Clin Oncol
|
2013
|
0.77
|
|
44
|
Clinical significance of insulin-like growth factor gene polymorphisms with survival in patients with gastrointestinal stromal tumors.
|
J Korean Surg Soc
|
2012
|
0.77
|
|
45
|
Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
|
Ann Hematol
|
2013
|
0.76
|
|
46
|
Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML.
|
Chonnam Med J
|
2011
|
0.76
|
|
47
|
Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.
|
Yonsei Med J
|
2014
|
0.75
|
|
48
|
No association of the hypoxia-inducible factor-1α gene polymorphisms with survival in patients with colorectal cancer.
|
Med Oncol
|
2010
|
0.75
|
|
49
|
Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer.
|
J Korean Med Sci
|
2007
|
0.75
|
|
50
|
Prognostic Impact of Polymorphisms in the CASPASE Genes on Survival of Patients with Colorectal Cancer.
|
Cancer Res Treat
|
2012
|
0.75
|
|
51
|
Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|
|
52
|
Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia.
|
Acta Haematol
|
2011
|
0.75
|
|
53
|
Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors.
|
Ann Hematol
|
2010
|
0.75
|
|
54
|
AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer.
|
Oncology
|
2016
|
0.75
|
|
55
|
No association of the eNOS gene polymorphisms with survival in patients with colorectal cancer.
|
Med Oncol
|
2010
|
0.75
|
|
56
|
Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer.
|
J Cancer Res Clin Oncol
|
2014
|
0.75
|
|
57
|
Gold-installed biostable nanocomplexes for tumor-targeted siRNA delivery in vivo.
|
Chem Commun (Camb)
|
2015
|
0.75
|